Management

Jim has been with Aminex since 2012. He was one of six top executives with NASA’s Apollo lunar landing program management, and he has spent almost 40 years in several corporate leadership positions in high-tech electronics systems, heavy infrastructure maintenance equipment manufacturing, and biotech drug development. Jim is retired chairman of Alamo Group, Inc. (NYSE) Prior to that, as chairman, CEO, and president of Tracor Inc., he led the turnaround and six times growth of Tracor in the defense electronics industry with 10,000 employees. Tracor was a Fortune 100 Fastest Growing Company. Jim graduated with a bachelor’s degree in mechanical engineering from the University of Washington and has received numerous honorary awards.

Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.

Dr. Kathy Fosnaugh has 25 years of experience in biotech research and development. Most recently she was Director of Research at Youtell Biochemical. Prior to this, as Associate Director of Discovery Research and Pharmaceutical Development at Marina Therapeutics (formerly Nastech Pharmaceuticals), Dr. Fosnaugh was instrumental in nucleic acid therapeutics and delivery programs in cancer, autoimmune, and metabolic disease areas. Previously she held scientist positions at Sirna Therapeutics and Ligand Pharmaceuticals. She has published 13 scientific articles and co-authored 17 patents. Kathy received her BS and PhD degrees in microbiology from the University of Illinois and Cornell University, respectively, followed by postdoctoral research in developmental biology at the University of California, San Diego.

Jeff Judson has a cross-cutting responsibility at Aminex in investor recruitment, regulatory oversight, communications, and project management. His career spans 35 years of working on Capitol Hill, studying and influencing public and regulatory policy at all levels of government as a think tank president and later assisting corporations and trade associations to overcome regulatory obstacles.

Nicole Gallegos, is responsible for directing Clinical Trial operations for Aminex. She has over 17 years of industry experience in both Clinical Operations and Clinical Data Management working for multiple pharmaceutical, biotechnology, medical device, and contract research organizations, including management and leadership of global teams. Nicole is an experienced program manager with strong knowledge of clinical operations, data management, regulatory data requirements, clinical trial process, biostatistics, quality management, and systems applications. She graduated from Belmont University in Nashville, TN with an MBA and concentration in Health Care Management. Prior to graduate work she received a Bachelors of Science in Biology with a pre-medicine focus from the University of Texas San Antonio.

Greg is currently President of CTM Solutions, LLC, a CMC and clinical trial materials consultancy. He has over 20 years’ experience in GLP, GMP and GCP regulated drug product development, and is a subject matter expert in drug substance synthesis, scale up, process development, and analytical characterization. He also provides regulatory CMC guidance. Greg completed his PhD in Biological Chemistry, at the University of Guelph, Ontario, Canada and postdoctoral training at University of Denver. He has held positions of increasing responsibility at Synthetech, Cell Therapeutics, and SNBL USA. Most recently Dr. Coulter has worked on development teams leading to the FDA approval of the weight loss drug Contrave and the PI3K delta inhibitor Zydelig.

Jackie Walling, MBChB, PhD, is a British trained physician scientist and the principal of a consulting group that provides expertise on a wide range of global drug development and regulatory projects in oncology and rare diseases. Her leadership has directly impacted the successful development and regulatory approval of several medicines including gemcitabine, pemetrexed, elosulfase, relugolix and talazoparib. Dr. Walling received an MBChB from the University of Bristol and BSc and PhD degrees from the University of Southampton, UK.